AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23485342 — intervention group
Group type: EXPERIMENTAL
Intervention: Clothing made of cellulose fibers with seaweed enriched with silver ions
Number of subjects: 19
Study 23485342 — intervention group
Group type: COMPARATOR
Intervention: Placebo clothing (control group)
Number of subjects: 19
Study 20538132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of furosemide (mean dose 162 ± 48 mg/24 hours)
Number of subjects: 41
Study 20538132 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of furosemide (mean dose 162 ± 52 mg/24 hours)
Number of subjects: 41
Study 18412301 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating procedure device (RPD)
Number of subjects: 47
Study 18412301 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 47
Study 17009113 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2 microg/kg) with midazolam (0.05 mg/kg)
Number of subjects: 150
Study 17009113 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg/kg) with midazolam (0.05 mg/kg)
Number of subjects: 150
Study 17009113 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (2 mg/kg) with midazolam (0.05 mg/kg)
Number of subjects: 150
Study 12699522 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial diabetes training for the emergency team and standardized protocol for prehospital emergency therapy of severe hypoglycaemia (SH)
Number of subjects: 7804
Study 12699522 — intervention group
Group type: EXPERIMENTAL
Intervention: Education of insulin-treated patients about their diabetes
Number of subjects: 7804
Study 12699522 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory additional glucose infusions and hospitalization for sulfonylurea-induced SH
Number of subjects: 7804
Study 11083314 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (30 microg/kg IV)
Number of subjects: 65
Study 11083314 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 65
Study 8928243 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily for 24 months
Number of subjects: 707
Study 8928243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707
Study 1352012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis alone
Number of subjects: 18
Study 1352012 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger
Number of subjects: 18
Study 1352012 — intervention group
Group type: EXPERIMENTAL
Intervention: Excitement
Number of subjects: 18
Study 1352012 — intervention group
Group type: EXPERIMENTAL
Intervention: Happiness
Number of subjects: 18
Study 6430439 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintiphotography with gallium‐67 (67Ga)
Number of subjects: 34
Study 6430439 — intervention group
Group type: EXPERIMENTAL
Intervention: Determination of renal beta 2 microglobulin excretion
Number of subjects: 34
Study 6430439 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunofluorescence of antibody coated bacteria
Number of subjects: 34
Study 6430439 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintiphotography with 67Ga and determination of renal beta 2 microglobulin excretion
Number of subjects: 34
Study 6430439 — intervention group
Group type: COMPARATOR
Intervention: Excretion of beta 2 microglobulin and uptake of 67Ga in patients with lower urinary tract infections
Number of subjects: 34
Study 31775414 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation through foramen rotundum (FR)
Number of subjects: 80
Study 31775414 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency thermocoagulation through foramen ovale (FO)
Number of subjects: 80
Study 31775414 — intervention group
Group type: COMPARATOR
Intervention: Gasserian ganglion ablation through the Hartel approach (FO)
Number of subjects: 80
Study 31099333 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/day magnesium oxide
Number of subjects: 36
Study 31099333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 27067676 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight weekly one hour meditation‐focused mind/body classes teaching concentration and insight meditation skills along with mind/body exercises.
Number of subjects: 41
Study 27067676 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight weekly one hour meditation‐focused mind/body classes.
Number of subjects: 41
Study 24436297 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (10 mg)
Number of subjects: 20
Study 24436297 — intervention group
Group type: COMPARATOR
Intervention: Control (AB individuals)
Number of subjects: 20
Study 22496437 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser CCC (femtosecond laser-created continuous circular capsulotomy)
Number of subjects: 45
Study 22496437 — intervention group
Group type: COMPARATOR
Intervention: Manual CCC (manually performed continuous curvilinear capsulorrhexis)
Number of subjects: 45
Study 22496437 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser CCC
Number of subjects: 45
Study 19909984 — intervention group
Group type: EXPERIMENTAL
Intervention: De Vega procedure
Number of subjects: 210
Study 19909984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring annuloplasty
Number of subjects: 210
Study 19909984 — intervention group
Group type: EXPERIMENTAL
Intervention: De Vega + pericardial patch augmentation
Number of subjects: 210
Study 19909984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring annuloplasty + pericardial patch augmentation
Number of subjects: 210
Study 18065019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaderm Absorbent dressing
Number of subjects: 40
Study 18065019 — intervention group
Group type: COMPARATOR
Intervention: Kaltostat dressing
Number of subjects: 40
Study 16275125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 1000
Study 16275125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 12111109 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioguanine (TG)
Number of subjects: 10
Study 12111109 — intervention group
Group type: COMPARATOR
Intervention: Mercaptopurine (MP)
Number of subjects: 10
Study 9892304 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 120
Study 9892304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8636474 — intervention group
Group type: EXPERIMENTAL
Intervention: Box-only resin composite restorations
Number of subjects: 68
Study 1975333 — intervention group
Group type: EXPERIMENTAL
Intervention: M37 vaccine (1 x 10(4) pfu)
Number of subjects: 90
Study 1975333 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent rotavirus vaccine (1 x 10(4) pfu each of serotype 3 RRV and human rotavirus‐RRV reassortants of serotypes 1, 2, and 4)
Number of subjects: 90
Study 1975333 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced quadrivalent vaccine (1 x 10(4) pfu of serotype 1 and 3 components but 5 x 10(4) pfu of serotype 2 and 4 components)
Number of subjects: 90
Study 1975333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 6791212 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 ml/kg alcohol
Number of subjects: 16
Study 6791212 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml/kg alcohol
Number of subjects: 16
Study 6791212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6791212 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 ml/kg alcohol
Number of subjects: 16
Study 30586738 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c ≥9.0% group
Number of subjects: 166
Study 30586738 — intervention group
Group type: COMPARATOR
Intervention: HbA1c ≤7.0% group
Number of subjects: 166
Study 30586738 — intervention group
Group type: EXPERIMENTAL
Intervention: Positivity for ≥2 AAbs during DCCT
Number of subjects: 166
Study 30586738 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≥2 AAbs
Number of subjects: 166
Study 28063245 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing
Number of subjects: 0
Study 28063245 — intervention group
Group type: COMPARATOR
Intervention: Non-genetic dosing
Number of subjects: 0
Study 26721142 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with acupoint embedding therapy
Number of subjects: 120
Study 26721142 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 120
Study 22672130 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) gluconate
Number of subjects: 48
Study 22672130 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% triclosan + 0.025% sodium fluoride (NaF) + 12% ethyl alcohol
Number of subjects: 48
Study 22672130 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CHX + 0.3% triclosan + 0.3% NaF + 0.09% Zn chloride (ZnCl(2))
Number of subjects: 48
Study 22672130 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 48
Study 21169640 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (40 mg/kg)
Number of subjects: 72
Study 21169640 — intervention group
Group type: COMPARATOR
Intervention: Control (no phenobarbital)
Number of subjects: 72
Study 19669885 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based preventive interventions delivered by community teams through the PROSPER model
Number of subjects: 12000
Study 19669885 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 12000
Study 17598009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (5,000 units/day until 20 weeks then 5,000 units q12h until 37 weeks or onset of labor)
Number of subjects: 91
Study 17598009 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 91
Study 15373928 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA formoterol (12 microg)
Number of subjects: 38
Study 15373928 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI formoterol (Foradil Aerolizer)
Number of subjects: 38
Study 15373928 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC formoterol (Foradil CFC inhalers)
Number of subjects: 38
Study 15373928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 11766869 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care anticoagulation management clinics
Number of subjects: 0
Study 11766869 — intervention group
Group type: COMPARATOR
Intervention: Secondary care anticoagulation management clinics
Number of subjects: 0
Study 9922066 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Hop to Health program (4-year randomized controlled trial)
Number of subjects: 0
Study 9922066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat Reduction Intervention Trial in African-Americans (5-year trial)
Number of subjects: 0
Study 7701277 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 22
Study 7701277 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 22
Study 7701277 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye tracking and autonomic responsivity
Number of subjects: 22
Study 7701277 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Number of subjects: 22
Study 7701277 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorodeoxyglucose positron emission tomography
Number of subjects: 22
Study 2959426 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg b.i.d. with increments of 2.5 mg b.i.d. at weekly intervals)
Number of subjects: 87
Study 2959426 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 to 10 mg b.i.d.)
Number of subjects: 87
Study 2959426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 2959426 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 87
Study 29635693 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 fractional laser treatment (one treatment each month) with topical 0.1% tacrolimus cream
Number of subjects: 45
Study 29635693 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.1% tacrolimus cream
Number of subjects: 45
Study 26541905 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-onset antiplatelet therapy (prasugrel or glycoprotein IIb-IIIa) in the prehospital setting
Number of subjects: 1452
Study 26541905 — intervention group
Group type: EXPERIMENTAL
Intervention: Calling earlier (time from onset to ECG <120 minutes)
Number of subjects: 1452
Study 26541905 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing time from diagnostic ECG to angiography (>90 minutes)
Number of subjects: 1452
Study 25070482 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral product of pioglitazone hydrochloride with increased hydroxypropyl cellulose (HPC)
Number of subjects: 0
Study 25070482 — intervention group
Group type: COMPARATOR
Intervention: Reference listed drug (RLD) pioglitazone hydrochloride
Number of subjects: 0
Study 23383006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial health warnings with increasing levels of warning intensity
Number of subjects: 3297
Study 23383006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial health warnings
Number of subjects: 3297
Study 20670726 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR-based treatment
Number of subjects: 2180
Study 20670726 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 2180
Study 20670726 — intervention group
Group type: COMPARATOR
Intervention: Both treatment strategies (Verapamil SR and Atenolol)
Number of subjects: 2180
Study 18414838 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual volumetry
Number of subjects: 41
Study 18414838 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeSurfer
Number of subjects: 41
Study 18414838 — intervention group
Group type: EXPERIMENTAL
Intervention: IBASPM
Number of subjects: 41
Study 18414838 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual volumetry and FreeSurfer
Number of subjects: 41
Study 18414838 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual volumetry and IBASPM
Number of subjects: 41
Study 16328200 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 75
Study 16328200 — intervention group
Group type: COMPARATOR
Intervention: Self-help manual
Number of subjects: 75
Study 12744767 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming therapy using a Warm Up device (n = 8)
Number of subjects: 33
Study 12744767 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 33
Study 11171790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of vitamin C
Number of subjects: 19
Study 11171790 — intervention group
Group type: COMPARATOR
Intervention: Sequential infusions of dobutamine (Dob, Dob-2) without vitamin C
Number of subjects: 19
Study 9394695 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with metronidazole for E. histolytica
Number of subjects: 110
Study 9394695 — intervention group
Group type: COMPARATOR
Intervention: Untreated children
Number of subjects: 110
Study 8179146 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of 2.5% thiopentone and 1% methohexitone (1:3 ratio)
Number of subjects: 120
Study 8179146 — intervention group
Group type: COMPARATOR
Intervention: Unmodified 1% methohexitone
Number of subjects: 120
Study 3445589 — intervention group
Group type: EXPERIMENTAL
Intervention: Live combined mumps-measles vaccine (MMV)
Number of subjects: 648
Study 3445589 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 648
Study 31159752 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message-enhanced clinical exercise rehabilitation program
Number of subjects: 36
Study 31159752 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical exercise rehabilitation program
Number of subjects: 36
Study 28753217 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless, flapless, and glueless intrascleral fixation of a standard three‐piece posterior chamber IOL
Number of subjects: 11
Study 28753217 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 11
Study 25128068 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 % formalin
Number of subjects: 120
Study 25128068 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 % formalin
Number of subjects: 120
Study 24643489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=816)
Number of subjects: 1224
Study 24643489 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=408)
Number of subjects: 1224
Study 20817053 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 2346
Study 20817053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2346
Study 18205961 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction and maintenance
Number of subjects: 1158
Study 18205961 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction with isoflurane/N2O
Number of subjects: 1158
Study 18205961 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/N2O maintenance
Number of subjects: 1158
Study 18205961 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/N2O alone
Number of subjects: 1158
Study 16875952 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually evoked potentials (VEP) with different visual stimulation tasks (checkerboard pattern and dartboard pattern)
Number of subjects: 0
Study 16875952 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher complexity of the checkerboard pattern and increasing visual field sections
Number of subjects: 0
Study 16875952 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency range of visual stimulation tasks
Number of subjects: 0
Study 14652862 — intervention group
Group type: EXPERIMENTAL
Intervention: Koch's second approach for covariate adjustment in randomized clinical trials
Number of subjects: 0
Study 14652862 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical ANCOVA for continuous response
Number of subjects: 0
Study 14652862 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction factor for Koch's test statistic
Number of subjects: 0
Study 11813764 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a cardiac rehabilitation programme (CRP)
Number of subjects: 240
Study 11813764 — intervention group
Group type: COMPARATOR
Intervention: Not participating in a cardiac rehabilitation programme (CRP)
Number of subjects: 240
Study 9106373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) with ERT
Number of subjects: 358
Study 9106373 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ERT
Number of subjects: 358
Study 9106373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) without ERT
Number of subjects: 358
Study 9106373 — intervention group
Group type: COMPARATOR
Intervention: Placebo without ERT
Number of subjects: 358
Study 8385294 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine and prednisolone
Number of subjects: 106
Study 8385294 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin and prednisolone
Number of subjects: 106
Study 8385294 — intervention group
Group type: EXPERIMENTAL
Intervention: Total material (both groups)
Number of subjects: 106
Study 8385294 — intervention group
Group type: EXPERIMENTAL
Intervention: Total material (cessation of graft function as endpoint)
Number of subjects: 106
Study 31482224 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib plus gemcitabine (GG)
Number of subjects: 297
Study 31482224 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus placebo (GP)
Number of subjects: 297
Study 28619701 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (12 weeks, structured interactive sessions, therapist support upon request)
Number of subjects: 180
Study 28619701 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 180
Study 28619701 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (unguided Web-based psycho-education)
Number of subjects: 180
Study 25464897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulfate/magnesium citrate
Number of subjects: 200
Study 25464897 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol with ascorbic acid
Number of subjects: 200
Study 23421595 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal preputial flap (group A)
Number of subjects: 130
Study 23421595 — intervention group
Group type: COMPARATOR
Intervention: Ventral dartos flap (group B)
Number of subjects: 130
Study 21226937 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive therapy (CT) while tapering antidepressants (AD)
Number of subjects: 276
Study 21226937 — intervention group
Group type: COMPARATOR
Intervention: Maintenance antidepressants (AD)
Number of subjects: 276
Study 21226937 — intervention group
Group type: COMPARATOR
Intervention: Combination of brief cognitive therapy (CT) with maintenance antidepressants (AD)
Number of subjects: 276
Study 21226937 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation (using a societal perspective)
Number of subjects: 276
Study 18211999 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 106
Study 18211999 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 106
Study 16429900 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable 4‐0 braided polyglycolic acid sutures (Sentesorb) in the upper half of the incision
Number of subjects: 60
Study 16429900 — intervention group
Group type: COMPARATOR
Intervention: 4‐0 nonabsorbable monofilamentous polypropylene suture (Monoplene) in the lower half of the incision
Number of subjects: 60
Study 16429900 — intervention group
Group type: COMPARATOR
Intervention: Lower half of the incision (both groups)
Number of subjects: 60
Study 12739706 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily (o.d.)
Number of subjects: 440
Study 12739706 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily (b.i.d.)
Number of subjects: 440
Study 12739706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 10561627 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (50 microg at 4-hour intervals for a maximum of 6 doses)
Number of subjects: 200
Study 10561627 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter plus oxytocin (maximum dose of 36 mU/min)
Number of subjects: 200